Tagged with LG

Celgene As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a company with a smaller product portfolio of predominantly innovative medicines in haematology and oncology, it makes sense that the government looks to cut costs in the generic…

Celgene Russia Celegene did not have a Russian affiliate office during Focus Reports’ initial report on Russia in 2006. What attracted Celgene’s relatively recent entrance into this market? We had external and internal reasons, which coincided in this case. The external reason was the launch of the reimbursement system in Russia, which…

Celgene Taiwan Could you please give our readers an overview of the importance of Taiwan for Celgene in a regional and a global context? What is attractive in Taiwan for Celgene? Celgene is very new entrant in the multinational context as a latecomer to the market. As a biopharmaceutical company it is…

LG Life Sciences LG Life Sciences seems quite unique among the rest of pharmaceutical companies in Korea which tend to be family owned. How has this set LGLS apart in terms of its development and strategy in the industry? Traditionally, companies in Korea have focused on generic drugs and in-licensing new medicines, so…

Celgene France In only four years Celgene has introduced a number of important products in the French market and is now seen as a preeminent biopharmaceutical company in hematology. As the head of Celgene France’s operations, what were the main milestones of the company since its establishment in the French market in…

Celgene Germany Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a small legal entity in a still smaller office at the airport in Munich without even a computer! Three years later…